Skip to main
  1. Stocks
  2. Denali Therapeutics
  3. Forecast
DNLI

Denali Therapeutics (DNLI) Stock Forecast & Price Target

Denali Therapeutics (DNLI) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Denali Therapeutics is viewed favorably because its TfR-based BBB transport platform can deliver both systemic and CNS therapies with potentially lower development risk, while addressing high-unmet-need neurodegenerative and rare disease targets. Commercially, AVLAYAH is validating the platform with 3Q26 net product revenue of $17.8M, a beat versus expectations, 4Q26 guidance of $30.0M to $32.0M, and access expanding to more than 70% of U.S. commercial lives plus 20 state Medicaid programs. Its balance sheet and pipeline also support the thesis, with about $1.0B in cash after the PRV sale and several catalysts expected in 1H27 and 2027 across DNL593, DNL628, DNL952, DNL921, DNL151, and zafinofusp alfa.

Bears say

Denali Therapeutics is vulnerable to regulatory uncertainty because its reliance on accelerated review paths does not eliminate the risk that regulators will demand additional data, change approval standards, or require longer studies. Such outcomes could delay commercialization and weaken the company’s competitive position if approved products fail to secure labels with the necessary features to gain traction in the market. Financially, the company will likely need to access capital markets to fund ongoing development, and any difficulty raising funds could constrain cash resources and slow or impair completion of its programs.

Denali Therapeutics (DNLI) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Denali Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Denali Therapeutics (DNLI) Analyst Forecast & Price Prediction

Get the latest Denali Therapeutics (DNLI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Denali Therapeutics (DNLI)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Denali Therapeutics (DNLI) Forecast

Analysts have given Denali Therapeutics (DNLI) a Buy based on their latest research and market trends.

According to 13 analysts, Denali Therapeutics (DNLI) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Denali Therapeutics (DNLI)


Denali Therapeutics (DNLI) Analyst Forecast & Price Prediction

Get the latest Denali Therapeutics (DNLI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Denali Therapeutics (DNLI)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DNLI stock data and trends